Drupal.behaviors.print = function(context) {window.print();window.close();}>
Regulus, GSK Ink Second miRNA Rx Collaboration
February 25, 2010
Regulus, GSK Ink Second miRNA Rx Collaboration
The newest deal will focus on miRNA-122, with hepatitis C infection as the initial indication.
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News
Santaris Nears End of Phase II Trial of miRNA HCV Rx, Seeks Partnership Since GSK Opted Out
September 15, 2011 / Gene Silencing News
EPO to Hear Mirrx Request for Resumption of Patent Proceedings Covering miRNA Rx Technology
January 20, 2011 / Gene Silencing News
Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News
Santaris Sues Mirrx Founder Over Blockmir Technology
May 6, 2010 / Gene Silencing News